{
    "clinical_study": {
        "@rank": "33553", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "Meropenem therapy with regimen routinely decided by attending physician"
            }, 
            {
                "arm_group_label": "Study group", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in Study group will accept meropenem therapy based on PPK and PD parameter."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a\n      population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract\n      infection patients."
        }, 
        "brief_title": "Meropenem Dosage Strategy Based on PPK Model", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Lower Respiratory Tract Infection", 
        "condition_browse": {
            "mesh_term": "Respiratory Tract Infections"
        }, 
        "detailed_description": {
            "textblock": "-  Subjects:lower respiratory tract infection patients\n\n        -  Study design:randomized control study.The patients in study group will accept meropenem\n           therapy with the regimen decided by a software developed from population\n           pharmacokinetic model and clinical pharmacodynamic parameter. The patients in control\n           group will accept meropenem therapy with the regimen decided by attending physician.\n\n        -  Primary endpoint: clinical successful rate of meropenem therapy. THe clinical\n           efficiency of meropenem therapy will be evaluated one week later from stop of meropenem\n           therapy.\n\n        -  Second endpoint:duration of meropenem therapy and amount of used antibiotics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients hospitalized at the Peking University Third Hospital with community-acquired\n             or hospital-acquired lower respiratory tract infection.\n\n          -  Sixty years and older.\n\n        Exclusion Criteria:\n\n          -  More than one pathogenic Gram-negative bacillus is isolated from tracheal aspirate or\n             sputum culture\n\n          -  younger than 60 years old\n\n          -  Positive HIV antibody titre\n\n          -  Had known or suspected tuberculosis or other infections caused by Gram-positive\n             cocci, viruses or fungi at baseline."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944319", 
            "org_study_id": "75505-01"
        }, 
        "intervention": {
            "arm_group_label": "Study group", 
            "description": "Meropenem therapy with regimen decided by a software developed from a PPK model and clinical PD parameter", 
            "intervention_name": "Meropenem therapy based on  PPK  and PD", 
            "intervention_type": "Drug", 
            "other_name": "Mepem, meropenem for injection"
        }, 
        "intervention_browse": {
            "mesh_term": "Meropenem"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Infection; Meropenem; Pharmacokinetics; Pharmacodynamics", 
        "lastchanged_date": "September 12, 2013", 
        "location": {
            "contact": {
                "email": "zhouqingtaobysy@sina.com", 
                "last_name": "Qingtao Zhou, MD", 
                "phone": "86-10-82265562"
            }, 
            "facility": {
                "address": {
                    "city": "Haidian District", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100191"
                }, 
                "name": "Peking University Third Hospita"
            }, 
            "investigator": {
                "last_name": "Qingtao Zhou, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients", 
        "other_outcome": {
            "description": "Record the cost of antibiotic therapy", 
            "measure": "Cost of antibiotic therapy", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed for the duration of antibiotic therapy, an expected average of 10 days"
        }, 
        "overall_contact": {
            "email": "zhouqingtaobysy@sina.com", 
            "last_name": "Qingtao Zhou, MD", 
            "phone": "86-10-82265562"
        }, 
        "overall_official": {
            "affiliation": "Peking University Third Hospital", 
            "last_name": "Qingtao Zhou, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clinical success or failure of meropenem therapy will be evaluated one week after stop of antibiotic therapy", 
            "measure": "Clinical success rate", 
            "safety_issue": "Yes", 
            "time_frame": "One week after antibiotic therapy finished."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944319"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University Third Hospital", 
            "investigator_full_name": "Qingtao Zhou", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Record the amount of antibiotic usage during antibiotic therapy", 
            "measure": "Amount of antibiotic", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of antibiotic therap, an expected average of 10 days"
        }, 
        "source": "Peking University Third Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qingtao Zhou", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}